Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for eight therapies that received regulatory approval in 2022. The approvals from the US Food and Drug Administration (FDA) included one Biologics License Application (BLA), five New Drug Applications (NDAs), and one Supplemental New Drug Application (sNDA). One Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was approved, and collectively most of the approvals were for therapies targeting a rare disease. Veristat’s success in preparing marketing applications that receive approval can be attributed to the ability of our integrated teams to navigate the complex regulatory submission process with the FDA and regulators around the world.
“At Veristat, we believe championing better health not only equates to finding cures for diseases but also improving patients’ abilities to more ably live with their disease,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “A key measure of our success is how effectively we advance the numerous possibilities for novel innovation to improve the quality and duration of human life. While it’s important to recognize our progress in advancing treatments through the development and approval process, there is more work to do, particularly in the area of rare diseases.”
According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases and only 5% of known rare diseases have one or more approved treatments. With February Rare Disease month, Veristat teams reaffirm their commitment to advancing rare disease research across several modalities that span gene therapies, cell therapies, and tissue engineering— including the first gene therapy approved in the Western world.
In the last three years, Veristat teams have:
- Conducted 190+ rare disease projects for over 110 sponsors working on rare disease treatments
- Prepared 30+ INDs and CTAs for rare disease therapies
- Supported 55 Marketing Applications/Authorizations, of which 40% were for rare disease therapies
- Celebrated the success of clients receiving more than 25 regulatory approvals for marketing applications prepared by Veristat teams, 75% of which were for rare disease therapies.
From regulatory pathway selection to patient recruitment and site access difficulties to the intricacies of data collection, a rare disease therapy requires an extraordinary amount of coordination and scientific understanding. Effective utilization of natural history studies and decentralized clinical trial deployment can be valuable.
“Rare disease research presents many challenges for trial design and regulatory strategy,” stated John Balser, Ph.D., Veristat Founder, President, and Chief Statistical Officer. “Small population sizes, uncertainty in clinical endpoint requirements, and an often limited understanding of the physiological basis of the disease can make for a difficult path forward. Over 30% of Veristat’s work is in rare diseases. The knowledge we have amassed has been game-changing for sponsors. Our creative approaches have helped them overcome daunting evidentiary and regulatory hurdles to gain swift and successful therapy approval.”
About Veristat
Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. With more than 28 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any program’s clinical, regulatory, statistical, data, or operational challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving patients’ lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005100/en/
Contact information
Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H2SITE Secures EIC Accelerator Funding to Deploy a Flagship 1 TPD Ammonia Cracker Using Membrane Reactor Technology at a Port in North-West Europe3.7.2025 09:40:00 EEST | Press release
H2SITE has been awarded the EIC (European Innovation Council) Accelerator program for a project aimed at deploying a first-of-its-kind ammonia cracking unit capable of producing 1 ton of high-purity hydrogen per day. The system is based on H2SITE’s proprietary palladium-based membrane reactor technology, which enables the simultaneous catalytic decomposition of ammonia and selective hydrogen separation within a single unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702142283/en/ Ammonia Cracker using Membrane Reactor Technology This breakthrough technology offers several compelling advantages over conventional ammonia cracking processes: Lowest Levelized Cost of Hydrogen (LCOH) from ammonia due to high efficiency and integrated operation Reduced energy consumption, operating at significantly lower temperatures (400–450 °C) than traditional cracking methods (typically 600–800 °C) High-purity hydrogen output, compliant
ISDA and Ant International Lead New Industry Report on Use of Tokenised Bank Liabilities for FX Settlement and Cross-Border Payments Under Project Guardian3.7.2025 09:00:00 EEST | Press release
The International Swaps and Derivatives Association (ISDA) and Ant International led the Project Guardian FX industry group to develop a new report for implementing tokenised bank liabilities and shared ledger in cross-border payments and foreign exchange (FX) settlement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702791535/en/ Report on Use of Tokenised Bank Liabilities for Transaction Banking by ISDA and Ant International, under the Monetary Authority of Singapore's (MAS) Project Guardian The joint report is produced under the Monetary Authority of Singapore's (MAS) Project Guardian, a global collaboration between policymakers and key industry players to enhance liquidity and efficiency of financial markets through asset tokenisation. ISDA and Ant International are members of the industry group and lead the FX workstream to develop FX data specifications, risk management frameworks and FX documentation. Other contri
Curve Pay and Thales Join Forces to Securely Transform Digital Wallets on iPhone3.7.2025 09:00:00 EEST | Press release
Curve, the ultimate digital wallet, today announced deepening its collaboration with Thales, the global leader in advanced technologies, delivering secure modern payment solutions for financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702696837/en/ Thales D1 Platform to power CURVE PAY (Photo: Thales) This partnership comes on the back of Curve launching Curve Pay on iOS, marking a watershed moment in mobile payments. This partnership is a significant step to reshaping everyday spending, allowing Curve customers to benefit from NFC payment directly in the Curve App for contactless payments in store for all end-users on iOS and Android. Curve Pay is underpinned by Thales’ D1 platform on iOS and Android in Europe which allows customers to digitize a payment card through a mobile wallet. The cloud-based D1 platform operates in real time, enabling seamless integration with existing systems to deliver secur
Medimaps Group Launches In Europe TBS Osteo Next-Generation Software For Advanced Bone Microarchitecture Assessment3.7.2025 09:00:00 EEST | Press release
Medimaps Group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, announces the European launch of its MDR-cleared next-generation TBS Osteo Advanced software. Following the product launch in the United States last month, this next milestone reflects the company's commitment to advancing osteoporosis detection and bone health management worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702082335/en/ Medimaps' TBS Osteo next-generation software The TBS Osteo Advanced software delivers refined correction for soft tissue thickness anterior to the lumbar spine, ensuring inclusivity of TBS assessment across a wide range of body phenotypes. It also introduces new system management capabilities, allowing hospitals and healthcare networks to centrally manage the TBS software on their DXA systems fleet, and to standardize workflows across multiple locations. These improvements enhance operational
Year-old European startup Maisa named alongside Google and Amazon in elite list of leading AI agent vendors in top global US research reports by Gartner3.7.2025 02:01:00 EEST | Press release
Maisa, a rising star of enterprise AI, has been named by leading global research and advisory firm Gartner in its list of leading vendors for developing reliable AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702640749/en/ Maisa founders David Villalón and Manuel Romero Inclusion in Gartner’s 2025 Hype Cycle for AI and Hype Cycle for the Future of Work marks the first time a Spanish startup has been mentioned in these influential reports. The company, which is barely a year old and made its first raise of $5m+ from leading US investors last year, now finds itself named alongside global giants Amazon Web Services, Google, Salesforce and LangChain. The Gartner Hype Cycle for AI Agents provides an overview of emerging technologies in AI, helping organizations navigate the evolving landscape of autonomous software agents. The Hype Cycle for the Future of Work provides CIOs with a crucial human-first lens on the tra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom